PensionDanmark Pensionsforsikringsaktieselskab Buys 54,260 Shares of Merck & Co., Inc. $MRK

Key Points

• PensionDanmark increased its Merck stake by 13.3% in the second quarter, purchasing 54,260 shares and bringing its total holdings to 462,927 shares valued at approximately $59.5 million.
• Merck reported quarterly revenue of $16.61 billion, exceeding estimates, while revenue rose 5.1% year over year. Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and a $134.56 price target.
• Keytruda remains both a growth driver and a risk: new approvals and pipeline initiatives support diversification, but the approaching 2028 patent cliff and a discontinued tulisokibart indication create execution and revenue-replacement challenges.

PensionDanmark Pensionsforsikringsaktieselskab raised its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 13.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 462,927 shares of the company's stock after buying an additional 54,260 shares during the quarter. PensionDanmark Pensionsforsikringsaktieselskab's holdings in Merck & Co., Inc. were worth $59,486,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $25,000. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. during the fourth quarter worth $26,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $26,000. High Note Wealth LLC increased its position in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after buying an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in Merck & Co., Inc. during the 4th quarter worth $31,000. Institutional investors and hedge funds own 76.07% of the company's stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst price-target increase: Guggenheim raised its Merck price target from $145 to $146 and maintained a Buy rating, implying meaningful upside from the referenced share price. This reinforces positive Wall Street sentiment. Benzinga
• Positive Sentiment: Keytruda gains another approval: Health Canada approved Keytruda with enfortumab vedotin for certain cisplatin-ineligible patients with muscle-invasive bladder cancer, expanding the drug’s use and potentially supporting sales before its major patent expirations. Health Canada approves Keytruda treatment
• Positive Sentiment: Pipeline and post-Keytruda strategy: Merck’s second-quarter commentary highlighted new product launches, pipeline progress and efforts to diversify into areas including vaccines, infectious diseases, hematology, cardiopulmonary disease and obesity. The company also raised its 2026 sales outlook, improving confidence in near-term execution. MRK Q2 earnings call
• Neutral Sentiment: Dividend comparison: Merck’s latest results have renewed debate over whether it offers a better income opportunity than Pfizer. The discussion may attract dividend-focused investors, but it does not represent a new company-specific catalyst. Pfizer or Merck dividend comparison
• Negative Sentiment: Keytruda patent risk remains central: Keytruda is approaching a significant patent cliff beginning in 2028. Merck is accelerating acquisitions and partnerships to offset the eventual revenue decline, but those investments can pressure earnings and increase execution risk. Merck is racing beyond Keytruda
• Negative Sentiment: Mixed pipeline development: Merck discontinued tulisokibart development in systemic sclerosis-associated interstitial lung disease, although the drug continues to be evaluated in other indications. The setback highlights clinical-development risk as Merck builds its post-Keytruda portfolio. MSD anti-TL1A trial update

Merck & Co., Inc. Price Performance

MRK stock opened at $128.27 on Friday. The stock has a 50-day moving average price of $123.78 and a two-hundred day moving average price of $119.04. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $135.05. The stock has a market cap of $316.81 billion, a PE ratio of 102.62, a price-to-earnings-growth ratio of 5.14 and a beta of 0.19. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The company's quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts forecast that Merck & Co., Inc. will post 2.72 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 272.00%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on MRK. CICC Research started coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an "outperform" rating and a $138.00 price target on the stock. BMO Capital Markets boosted their price objective on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. Wall Street Zen cut Merck & Co., Inc. from a "buy" rating to a "hold" rating in a research note on Monday, July 20th. Wells Fargo & Company raised their target price on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an "overweight" rating in a report on Wednesday, July 8th. Finally, Citigroup assumed coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a "neutral" rating and a $125.00 price target on the stock. Thirteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of "Moderate Buy" and a consensus price target of $134.56.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source